Clinical Advancements in the Targeted Therapies against Liver Fibrosis
暂无分享,去创建一个
[1] R. Sarpong,et al. Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.
[2] J. Ladero,et al. Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.
[3] Chiun Hsu,et al. Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. , 2017, Radiology.
[4] Non-Invasive Evaluation of Liver Fibrosis: 2-D Shear Wave Elastography, Transient Elastography or Acoustic Radiation Force Impulse Imaging? , 2016, Ultrasound in medicine & biology.
[5] M. Ciarleglio,et al. Liver and Spleen Stiffness Measurements by Point Shear Wave Elastography via Acoustic Radiation Force Impulse , 2016, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[6] M. Christie,et al. Acoustic radiation force impulse accuracy and the impact of hepatic steatosis on liver fibrosis staging , 2016, Journal of medical imaging and radiation oncology.
[7] G. Maddern,et al. Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis , 2016, International Journal of Colorectal Disease.
[8] Cher Heng Tan,et al. Magnetic Resonance Elastography and Other Magnetic Resonance Imaging Techniques in Chronic Liver Disease: Current Status and Future Directions , 2016, Gut and liver.
[9] H. Goto,et al. Liver stiffness measurement using acoustic radiation force impulse elastography in hepatitis C virus‐infected patients with a sustained virological response , 2016, Alimentary pharmacology & therapeutics.
[10] M. Gebel,et al. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients , 2016, Alimentary pharmacology & therapeutics.
[11] R. Moirand,et al. Acoustic radiation force impulse imaging for assessing liver fibrosis in alcoholic liver disease. , 2016, World journal of gastroenterology.
[12] A. Somasunderam,et al. Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment , 2016, Clinical and translational science.
[13] Shengzhen Tao,et al. Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study , 2016, The American Journal of Gastroenterology.
[14] M. Saag,et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus , 2016, AIDS.
[15] B. Taouli,et al. Magnetic Resonance Imaging/Elastography Is Superior to Transient Elastography for Detection of Liver Fibrosis and Fat in Nonalcoholic Fatty Liver Disease. , 2016, Gastroenterology.
[16] A. K. Sivrioğlu,et al. Noninvasive Evaluation of Liver Fibrosis: Is Acoustic Radiation Force Impulse a Useful Tool for Evaluating Liver Fibrosis in Patients With Chronic Hepatitis B and C? , 2016, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[17] Rohit Loomba,et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy‐proven nonalcoholic fatty liver disease: A prospective study , 2016, Hepatology.
[18] Ting Lin,et al. New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials , 2016, Front. Pharmacol..
[19] P. Trivedi,et al. Obeticholic acid for the treatment of primary biliary cirrhosis , 2016, Expert review of clinical pharmacology.
[20] J. Trebicka,et al. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. , 2016, Gastroenterology.
[21] Hildebrand Dijkstra,et al. The Fontan circulation and the liver: A magnetic resonance diffusion-weighted imaging study. , 2016, International journal of cardiology.
[22] R. Ehman,et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis , 2016, European Radiology.
[23] A. Ba-Ssalamah,et al. The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepato-specific contrast-enhanced sequences in staging liver fibrosis—a multiparametric approach , 2016, European Radiology.
[24] L. Castéra. Is it really worth adapting liver stiffness cut‐offs according to AST levels? , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[25] D. Dumitrascu,et al. Non‐invasive assessment of liver fibrosis in chronic viral hepatitis , 2015, European journal of clinical investigation.
[26] Gary K. Schwartz,et al. Tumour exosome integrins determine organotropic metastasis , 2015, Nature.
[27] Natalie J Torok,et al. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014 , 2015, Hepatology.
[28] G. Marchesini,et al. Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value , 2015 .
[29] Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.
[30] Yinan Wang,et al. Galactose-based Thermosensitive Nanogels for Targeted Drug Delivery of Iodoazomycin Arabinofuranoside (IAZA) for Theranostic Management of Hypoxic Hepatocellular Carcinoma. , 2015, Biomacromolecules.
[31] B. Keil,et al. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. , 2015, Journal of hepatology.
[32] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[33] C. Weston,et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. , 2015, The Journal of clinical investigation.
[34] K. Lindor,et al. Current research on the treatment of primary sclerosing cholangitis. , 2015, Intractable & rare diseases research.
[35] Zhengping Zhang,et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy. , 2015, ACS nano.
[36] Pier P. Paoli,et al. MeCP2 exerts global control over the myofibroblast transcriptome and reveals new regulators of fibrosis , 2015 .
[37] T. Luedde,et al. Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. , 2015, Biomaterials.
[38] G. Chertow,et al. Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease , 2014, Nephron.
[39] F. Tacke,et al. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. , 2014, Hepatobiliary surgery and nutrition.
[40] Carlo La Vecchia,et al. Hepatocellular carcinoma epidemiology. , 2014, Best practice & research. Clinical gastroenterology.
[41] R. Pellicciari,et al. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. , 2014, Current topics in medicinal chemistry.
[42] O. Stojadinović,et al. Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[43] S. Agarwal. Integrins and cadherins as therapeutic targets in fibrosis , 2014, Front. Pharmacol..
[44] R. Brown, Jr.,et al. Review article: the endocannabinoid system in liver disease, a potential therapeutic target , 2014, Alimentary pharmacology & therapeutics.
[45] Anthony D. Schmitt,et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma , 2014, Hepatology.
[46] Jian-hai Chen,et al. Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[47] Manmohan J. Singh,et al. Biological drug products : development and strategies , 2014 .
[48] S. Friedman,et al. Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease , 2013, PloS one.
[49] Q. Yuan,et al. Specific gene delivery to liver sinusoidal and artery endothelial cells. , 2013, Blood.
[50] Korbinian Brand,et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.
[51] S. Jalkanen,et al. Preclinical Evaluation of a Radioiodinated Fully Human Antibody for In Vivo Imaging of Vascular Adhesion Protein-1–Positive Vasculature in Inflammation , 2013, The Journal of Nuclear Medicine.
[52] Cui Tang,et al. Multifunctional polymeric nanoparticles for oral delivery of TNF-α siRNA to macrophages. , 2013, Biomaterials.
[53] J. Prakash,et al. Enhanced Effectivity of an ALK5-Inhibitor after Cell-Specific Delivery to Hepatic Stellate Cells in Mice with Liver Injury , 2013, PloS one.
[54] COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASES RELATED APPLICATIONS , 2013 .
[55] T. Sauerbruch,et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.
[56] Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). , 2012, Family practice.
[57] E. Pękala,et al. Monoclonal antibodies in targeted therapy. , 2012, Postepy higieny i medycyny doswiadczalnej.
[58] Lan Wei,et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. , 2012, Journal of hepatology.
[59] S. Chang,et al. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[60] X. Wang,et al. MicroRNAs in liver disease. , 2012, Gastroenterology.
[61] Cao Xie,et al. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[62] B. Hinz,et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.
[63] P. Workman,et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.
[64] A. Gudkov,et al. Small Molecule Drugs and Targeted Therapies for Neuroblastoma , 2012 .
[65] W. Stoorvogel. Functional transfer of microRNA by exosomes. , 2012, Blood.
[66] T. Reiberger,et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study , 2012, Alimentary pharmacology & therapeutics.
[67] W. Marsden. I and J , 2012 .
[68] A. Feldstein,et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.
[69] A. Maruyama,et al. Evaluation of polyanion-coated biodegradable polymeric micelles as drug delivery vehicles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[70] T. Ichim,et al. Targeted Gene Silencing of TLR4 Using Liposomal Nanoparticles for Preventing Liver Ischemia Reperfusion Injury , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[71] Ruchi Bansal,et al. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. , 2011, Molecular pharmaceutics.
[72] D. Schuppan,et al. Novel engineered targeted interferon‐gamma blocks hepatic fibrogenesis in mice , 2011, Hepatology.
[73] C. Gandhi,et al. Roles of microRNA-29a in the Antifibrotic Effect of Farnesoid X Receptor in Hepatic Stellate Cells , 2011, Molecular Pharmacology.
[74] J. Prakash,et al. Reduction of Fibrogenesis by Selective Delivery of a Rho Kinase Inhibitor to Hepatic Stellate Cells in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.
[75] J. Prakash,et al. Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632 , 2011, Pharmaceutical Research.
[76] G. Godlewski,et al. Endocannabinoids in liver disease , 2011, Hepatology.
[77] C. Hellerbrand,et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. , 2010, Journal of hepatology.
[78] Scott C. Brown,et al. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives , 2011, Analytical and bioanalytical chemistry.
[79] R. Chung,et al. The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort , 2011, Digestive Diseases and Sciences.
[80] M. Kubera,et al. In vivo effects of pentoxifylline on enzyme and non‐enzyme antioxidant levels in rat liver after carrageenan‐induced paw inflammation , 2010, Cell biochemistry and function.
[81] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[82] Derek Marshall,et al. Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.
[83] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[84] M. Vaysberg,et al. Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor , 2010, The Journal of Biological Chemistry.
[85] R. Levine,et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. , 2010, Gastroenterology.
[86] R. Soininen,et al. The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. , 2010, Matrix biology : journal of the International Society for Matrix Biology.
[87] Yihui Deng,et al. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability , 2010, Drug delivery.
[88] R. Jonsson,et al. The Fibroblast Integrin α11β1 Is Induced in a Mechanosensitive Manner Involving Activin A and Regulates Myofibroblast Differentiation* , 2010, The Journal of Biological Chemistry.
[89] M. Sherman. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. , 2010, Seminars in liver disease.
[90] B. Taouli,et al. Diffusion-weighted MR imaging of the liver. , 2010, Radiology.
[91] A. Sanyal. ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients. , 2010, Annals of internal medicine.
[92] J. Talwalkar,et al. Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid , 2010, Digestive Diseases and Sciences.
[93] P. Calès,et al. FibroMètres : une famille de tests sanguins de fibrose hépatique avec une performance diagnostique et une applicabilité élevées en pratique clinique , 2009 .
[94] F. Oberti,et al. [FibroMeters: a family of blood tests for liver fibrosis with high diagnostic performance and applicability in clinical practice]. , 2009, Pathologie-biologie.
[95] D. Brenner,et al. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[96] R. Schwabe,et al. CCR2 promotes hepatic fibrosis in mice , 2009, Hepatology.
[97] F. Ginhoux,et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis , 2009, Hepatology.
[98] R. Schwabe,et al. CCR1 and CCR5 promote hepatic fibrosis in mice. , 2009, The Journal of clinical investigation.
[99] M. Mejías,et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.
[100] M. Fink,et al. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. , 2009, Ultrasound in medicine & biology.
[101] V. de Lédinghen,et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C , 2009, European journal of gastroenterology & hepatology.
[102] Fabrice Carrat,et al. Liver biopsy: the best, not the gold standard. , 2009, Journal of hepatology.
[103] J. Blenis,et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. , 2009, Cancer research.
[104] S. Friedman. Hepatic fibrosis -- overview. , 2008, Toxicology.
[105] D. H. Park,et al. Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model , 2008, Journal of Gastroenterology.
[106] S. Friedman. Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies. , 2008, Clinics in liver disease.
[107] Min Liu,et al. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[108] B. V. Van Beers,et al. MR elastography. , 2008, Gastroenterologie clinique et biologique.
[109] Douglas A Christensen,et al. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. , 2008, Ultrasonics.
[110] Ralph Sinkus,et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. , 2008, Gastroenterology.
[111] Laurent Castera,et al. Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.
[112] Junji Kato,et al. Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone , 2008, Nature Biotechnology.
[113] S. Lotersztajn,et al. Cellular Targeting of the Apoptosis-Inducing Compound Gliotoxin to Fibrotic Rat Livers , 2008, Journal of Pharmacology and Experimental Therapeutics.
[114] F. Roudot-thoraval,et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. , 2008, Gastroenterology.
[115] V. Trillet-lenoir,et al. [Targeted therapies in oncology]. , 2007, La Revue du praticien.
[116] J. Wang,et al. Cyclic Arg-Gly-Asp Peptide-Labeled Liposomes for Targeting Drug Therapy of Hepatic Fibrosis in Rats , 2007, Journal of Pharmacology and Experimental Therapeutics.
[117] A. Gressner,et al. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options , 2007, Comparative hepatology.
[118] S. Pol,et al. FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest , 2007, Hepatology.
[119] H. Yoshiji,et al. Blockade of renin–angiotensin system in antifibrotic therapy , 2007, Journal of gastroenterology and hepatology.
[120] R. N. Chakrabarti,et al. Hepatoprotective Activity of Liposomal Flavonoid against Arsenite-Induced Liver Fibrosis , 2007, Journal of Pharmacology and Experimental Therapeutics.
[121] C. Samuel,et al. The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease. , 2007, Advances in experimental medicine and biology.
[122] A. Gouw,et al. Targeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options Evaluated , 2007, Pharmaceutical Research.
[123] Mark W. Kieran,et al. Identification of fibroblast heterogeneity in the tumor microenvironment , 2006, Cancer biology & therapy.
[124] L. Bryan-Lluka,et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. , 2006, The American journal of pathology.
[125] D. Meijer,et al. The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.
[126] J. Iredale,et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[127] S. Kiani,et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats , 2006, Gut.
[128] G. Molema,et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[129] D. Rockey,et al. Noninvasive measures of liver fibrosis , 2006, Hepatology.
[130] D. Rockey,et al. Regulation of peroxisome proliferator-activated receptor- in liver fibrosis , 2006 .
[131] G. Baffet,et al. Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. , 2005, Journal of hepatology.
[132] S. Kawakami,et al. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes. , 2005, Journal of pharmaceutical sciences.
[133] Y. Baruch,et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. , 2005, Journal of hepatology.
[134] Toshikazu Nakamura,et al. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. , 2005, The American journal of pathology.
[135] N. Nikitakis,et al. Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. , 2005, Frontiers in bioscience : a journal and virtual library.
[136] A. Morelli,et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.
[137] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[138] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[139] C. Betsholtz,et al. The mesenchymal α11β1 integrin attenuates PDGF-BB-stimulated chemotaxis of embryonic fibroblasts on collagens , 2004 .
[140] V. Paradis,et al. Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.
[141] A. Desmoulière,et al. Normal and Pathologic Soft Tissue Remodeling: Role of the Myofibroblast, with Special Emphasis on Liver and Kidney Fibrosis , 2003, Laboratory Investigation.
[142] S. Jung,et al. Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies. , 2003, Protein expression and purification.
[143] G. Gabbiani,et al. The myofibroblast in wound healing and fibrocontractive diseases , 2003, The Journal of pathology.
[144] J. Hoofnagle,et al. Progression of fibrosis in chronic hepatitis C. , 2003, Gastroenterology.
[145] E. Schiff,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.
[146] D. Taverna,et al. The diverse roles of integrins and their ligands in angiogenesis. , 2002, Cold Spring Harbor symposia on quantitative biology.
[147] Kevin Barraclough,et al. I and i , 2001, BMJ : British Medical Journal.
[148] T. Hassanein,et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection , 2001, American Journal of Gastroenterology.
[149] P. Olinga,et al. Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats , 2001, Hepatology.
[150] S. Friedman,et al. Transcriptional Regulation in Hepatic Stellate Cells , 2001, Seminars in liver disease.
[151] S. Friedman,et al. Hepatic fibrosis. Pathogenesis and principles of therapy , 2001 .
[152] J. Bruzzi,et al. Liver biopsy. , 2001, The New England journal of medicine.
[153] R. Caporale,et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. , 2000, Gastroenterology.
[154] R. Bataller,et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.
[155] D. Kershenobich,et al. Hepatic Fibrosis , 1955, Gastroenterology.
[156] R. Stephenson. A and V , 1962, The British journal of ophthalmology.